HF
ENSC icon

HRT Financial’s Ensysce Biosciences ENSC Stock Holding History

HRT Financial’s Portfolio ENSC Stock Details ENSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15K Buy
+54,429
New +$19.7K ﹤0.01% 3952
2026
Q1 		– Sell
-24,491
Closed -$22K – 4031
2025
Q4 		$22K Buy
+24,491
New +$45.5K ﹤0.01% 2971
2024
Q4 		– Sell
-1,571
Closed -$5K – 2610
2024
Q3 		$5K Buy
+1,571
New +$9.53K ﹤0.01% 2266

Other funds holding ENSC

Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
TIAM2
Tru Independence Asset Management 2 Portland, Oregon $185M AUM 20.3% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return

HRT Financial's ENSC Position: Q2 2026 in Review

HRT Financial opened a new position in Ensysce Biosciences (ENSC) in Q2 2026: 54,429 shares worth $15K. The stake represents ﹤0.01% of the portfolio and ranks #3952 among its holdings. This is a return to the name: HRT Financial previously reported a position in ENSC as recently as Q4 2025.

HRT Financial first reported a position in ENSC in Q3 2024 and has held it in 3 quarters since. The position peaked at $22K in Q4 2025. 18 funds tracked by Wall St. Rank hold ENSC as of Q2 2026.

  • HRT Financial held 54,429 shares of Ensysce Biosciences worth $15K as of Q2 2026.
  • Ensysce Biosciences was a new HRT Financial position in Q2 2026.
  • Ensysce Biosciences made up ﹤0.01% of HRT Financial's portfolio in Q2 2026, its #3952 holding.
  • HRT Financial first reported a position in Ensysce Biosciences in Q3 2024 and has held it in 3 quarters since.
  • HRT Financial's Ensysce Biosciences position peaked at $22K in Q4 2025.
  • 18 funds tracked by Wall St. Rank held Ensysce Biosciences as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.